Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).

Massaccesi M, Ferro M, Cilla S, Balducci M, Deodato F, Macchia G, Valentini V, Morganti AG.

Int J Clin Oncol. 2013 Oct;18(5):784-91. doi: 10.1007/s10147-012-0462-0. Epub 2012 Aug 15.

PMID:
22892797
[PubMed - indexed for MEDLINE]
2.

A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.

Morganti AG, Balducci M, Salvati M, Esposito V, Romanelli P, Ferro M, Calista F, Digesù C, Macchia G, Ianiri M, Deodato F, Cilla S, Piermattei A, Valentini V, Cellini N, Cantore GP.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):92-7. doi: 10.1016/j.ijrobp.2009.04.064. Epub 2009 Aug 14.

PMID:
19683876
[PubMed - indexed for MEDLINE]
3.

Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.

Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1066-74. doi: 10.1016/j.ijrobp.2010.07.021. Epub 2010 Oct 6.

PMID:
20932651
[PubMed - indexed for MEDLINE]
4.

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.

PMID:
23425509
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.

Iuchi T, Hatano K, Kodama T, Sakaida T, Yokoi S, Kawasaki K, Hasegawa Y, Hara R.

Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):793-800. doi: 10.1016/j.ijrobp.2013.12.011. Epub 2014 Feb 1.

PMID:
24495592
[PubMed - indexed for MEDLINE]
6.

Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.

Panet-Raymond V, Souhami L, Roberge D, Kavan P, Shakibnia L, Muanza T, Lambert C, Leblanc R, Del Maestro R, Guiot MC, Shenouda G.

Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):473-8. doi: 10.1016/j.ijrobp.2008.04.030. Epub 2008 Jun 12.

PMID:
18554821
[PubMed - indexed for MEDLINE]
7.

A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme.

Monjazeb AM, Ayala D, Jensen C, Case LD, Bourland JD, Ellis TL, McMullen KP, Chan MD, Tatter SB, Lesser GJ, Shaw EG.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):743-8. doi: 10.1016/j.ijrobp.2010.10.018. Epub 2011 Jan 13.

PMID:
21236604
[PubMed - indexed for MEDLINE]
8.

Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.

Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):655-60. doi: 10.1016/j.ijrobp.2012.01.035. Epub 2012 Apr 5.

PMID:
22483738
[PubMed - indexed for MEDLINE]
9.

Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme--a dosimetric comparison.

Piroth MD, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C, Kaiser HJ, Langen KJ, Eble MJ.

Radiat Oncol. 2009 Nov 23;4:57. doi: 10.1186/1748-717X-4-57.

PMID:
19930657
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.

Dhermain F.

Chin J Cancer. 2014 Jan;33(1):16-24. doi: 10.5732/cjc.013.10217. Review.

PMID:
24384237
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost.

Ken S, Vieillevigne L, Franceries X, Simon L, Supper C, Lotterie JA, Filleron T, Lubrano V, Berry I, Cassol E, Delannes M, Celsis P, Cohen-Jonathan EM, Laprie A.

Radiat Oncol. 2013 Jan 2;8:1. doi: 10.1186/1748-717X-8-1.

PMID:
23280007
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma.

Yoon SM, Kim JH, Kim SJ, Khang SK, Shin SS, Cho YH, Jwa E, Park JH, Ahn SD.

Tumori. 2013 Jul-Aug;99(4):480-7. doi: 10.1700/1361.15098.

PMID:
24326836
[PubMed - indexed for MEDLINE]
13.

RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.

Chinnaiyan P, Won M, Wen PY, Rojiani AM, Wendland M, Dipetrillo TA, Corn BW, Mehta MP.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):880-4. doi: 10.1016/j.ijrobp.2013.04.036. Epub 2013 May 29.

PMID:
23725999
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial.

Sultanem K, Patrocinio H, Lambert C, Corns R, Leblanc R, Parker W, Shenouda G, Souhami L.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):247-52.

PMID:
14697445
[PubMed - indexed for MEDLINE]
15.

Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.

Passoni P, Reni M, Cattaneo GM, Slim N, Cereda S, Balzano G, Castoldi R, Longobardi B, Bettinardi V, Gianolli L, Gusmini S, Staudacher C, Calandrino R, Di Muzio N.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1000-6. doi: 10.1016/j.ijrobp.2013.09.012.

PMID:
24267968
[PubMed - indexed for MEDLINE]
16.

Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: a dose-escalation trial.

Ippolito E, Cellini N, Digesù C, Cilla S, Mantini G, Balducci M, Di Lallo A, Deodato F, Macchia G, Massaccesi M, Mattiucci GC, Tagliaferri L, Piermattei A, Cuscunà D, Morganti AG.

Urol Oncol. 2013 Jan;31(1):87-92. doi: 10.1016/j.urolonc.2010.10.005. Epub 2011 Apr 1.

PMID:
21458315
[PubMed - indexed for MEDLINE]
17.

Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.

Lauve A, Morris M, Schmidt-Ullrich R, Wu Q, Mohan R, Abayomi O, Buck D, Holdford D, Dawson K, Dinardo L, Reiter E.

Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):374-87.

PMID:
15380569
[PubMed - indexed for MEDLINE]
18.

Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.

Tsien CI, Brown D, Normolle D, Schipper M, Piert M, Junck L, Heth J, Gomez-Hassan D, Ten Haken RK, Chenevert T, Cao Y, Lawrence T.

Clin Cancer Res. 2012 Jan 1;18(1):273-9. doi: 10.1158/1078-0432.CCR-11-2073. Epub 2011 Nov 7.

PMID:
22065084
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.

Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M, Musib L, Nicol SJ, Thornton DE, Prados MD.

Neuro Oncol. 2010 Jun;12(6):608-13. doi: 10.1093/neuonc/nop070. Epub 2010 Feb 15.

PMID:
20156802
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.

Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F, Innocenzi G, Gagliardi FM, Salvati M, Minniti G, Frati A, Frati L, Vecchione A.

Anticancer Res. 2003 Nov-Dec;23(6D):5159-64.

PMID:
14981983
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk